Metastatic renal cell carcinoma (RCC) resulting from the hereditary loss of the von Hippel-Lindau (VHL) tumor suppressor gene is the leading cause of death in VHL patients due to the deleterious effects of the metastatic tumor(s). VHL functions in the destruction of the alpha subunits of the heterodimeric transcription factor, hypoxia-inducible factor (HIF-1a and HIF-2a), in normoxic conditions. When VHL function is lost, HIF-a protein is stabilized, and target hypoxia-inducible genes are transcribed. The process of tumor invasion and metastasis involves the destruction of the extracellular matrix, which is accomplished primarily by the matrix metalloproteinase (MMP) family of enzymes. Here, we describe a connection between the loss of VHL tumor suppressor function and the upregulation of membrane type-1 MMP (MT1-MMP) gene expression and protein. Specifically, MT1-MMP is upregulated in VHLÀ/À RCC cells through an increase in gene transcription, which is mediated by the cooperative effects of the transcription factors, HIF-2 and Sp1. Further, we identify a functional HIF-binding site in the proximal promoter of MT1-MMP. To our knowledge, this is the first report to show direct regulation of MT1-MMP by HIF-2 and to provide a direct link between the loss of VHL tumor suppressor function and an increase in MMP gene and protein expression.
Introduction
von Hippel-Lindau (VHL) disease resulting from the loss of the VHL tumor suppressor gene is a dominantly inherited familial cancer affecting several organ systems (Hes et al., 2001) . Life expectancy is greatly reduced for almost 45% of all VHL patients who develop metastatic renal cell carcinoma (RCC) in addition to other VHL primary tumors (Linehan et al., 2003) . As such, metastatic RCC is the leading cause of death in VHL patients due to complications associated with the metastatic tumors (Maher and Kaelin, 1997; Richards et al., 1998; Singh et al., 2001) . Interestingly, almost 80% of sporadic renal cell carcinoma are the result of mutations in the VHL gene (Barry and Krek, 2004) .
VHL mediates the cell's response to changes in oxygen tension by regulating the protein stability of hypoxia inducible factor a (HIF-1a and HIF-2a also known as EPAS1). In normoxia, VHL binds HIF-a through the recognition of two hydroxy-proline residues and polyubiquitinates HIF-a to target it for proteosomal degradation (Kaelin, 2002; Barry and Krek, 2004) . When a cell enters hypoxia, HIF-a protein is stabilized and partners with HIF-b (a constitutively expressed protein also known as ARNT1) to form the functional transcription factor HIF, which activates hypoxiainducible genes such as those involved in angiogenesis and glycolysis (i.e., VEGF, EPO1, PDGF, GLUT1) (Harris, 2002) . In VHL disease, the function of VHL is lost; therefore, the cell accumulates HIF-a protein and downstream target genes are thus transcribed.
To achieve metastasis, a tumor cell must disrupt cellcell and cell-extracellular matrix (ECM) contacts, migrate through stromal tissue, invade the basement membrane, and enter/exit the blood stream (Bogenrieder and Herlyn, 2003) . These steps are accomplished primarily by the activity of the matrix metalloproteinase (MMP) family of enzymes (Egeblad and Werb, 2002; Seiki, 2003) . Elevated levels of MMPs have been correlated with the invasiveness of several human cancers, as well as with other tumor phenotypes such as angiogenesis, cell proliferation, and resistance to apoptosis (McCawley and Matrisian, 2001; Egeblad and Werb, 2002) . Most MMPs are secreted from cells as zymogens requiring extracellular activation by serine proteases or other MMPs. In addition to proteolytic activation, normal MMP activity is controlled by tissue inhibitors of metalloproteinases (TIMPs), proteins which function by active site inhibition (Visse and Nagase, 2003) .
Membrane type-1 MMP (MT1-MMP), a membranebound MMP, degrades several ECM components, controls cell-ECM contacts, localizes to the leading edge of invasive cells, as well as activates latent MMP-2 (Lehti et al., 1998; Hotary et al., 2000; Mori et al., 2002; Seiki, 2003) . Interestingly, TIMP-2 plays a role in the mechanism of pro-MMP-2 activation by MT1-MMP, which requires a complex of all three proteins each at a specific stiochiometric ratio (Strongin et al., 1995) . Increased expression of MT1-MMP has been measured in several human carcinomas, and its expression correlates with increased invasiveness and growth of tumor cells (Sato et al., 1994; Kitagawa et al., 1999; Hotary et al., 2003; Iida et al., 2004) . Importantly, MT1-MMP expression is significantly higher in RCC tumors of later pathologic stage compared to early stage (Kitagawa et al., 1999) .
Although VHL has been implicated in playing a role in RCC tumor invasion and metastasis, more studies are required to clearly define the mechanisms involved (Barry and Krek, 2004) . Koochekpour et al. (1999) described an increase in basal MMP-2 and MMP-9 expression as well as a decrease in TIMP levels in RCC cells lacking VHL expression. They further demonstrated that MMP activity drives the invasive capability of VHL renal cell carcinoma cells in an in vitro system. As MT1-MMP activates pro-MMP-2, we hypothesized that MT1-MMP expression is also regulated by VHL in RCC cells. To investigate the mechanisms of MT1-MMP regulation in VHL renal cell carcinoma, we used cell lines derived from the human 786-0 renal cell carcinoma cell line.
Here we report that in the absence of VHL, RCC cells overexpress MT1-MMP on the levels of gene and protein expression. Our data support a model in which the loss of the VHL tumor suppressor and subsequent stability of HIF-2a leads to induction of MT1-MMP expression. We define the mechanism of upregulation as direct transcriptional activation of MT1-MMP by HIF-2 in coordination with Sp1. To our knowledge, this is the first report to demonstrate MT1-MMP as a HIFregulated gene and to suggest a role for MT1-MMP in VHL RCC tumor invasion and metastasis.
Results

MT1-MMP is overexpressed in RCC cells lacking VHL on the levels of gene and protein expression
We first analyzed MMP gene expression in RCC cells that express either wild-type VHL (WT8) or are null for VHL (pRc-9) using Northern blot analysis and real-time RT-PCR. The basal and inducible (by growth factors and cytokines) expression levels of MMP-1, MMP-2, MMP-3, MMP-9, MMP-13, and MT1-MMP were measured. Basal levels of MMP-1, MMP-3, and MMP-13 were too low to detect, and although MMP-1 was inducible, no significant difference in expression was observed between cell lines (data not shown). These data suggest a lack of regulation of these MMPs by VHL. In contrast, data for expression of MMP-2 and MMP-9 agreed with those of Koochekpour et al. (1999) in that the pRc-9 cells constitutively overexpressed these MMPs compared to the WT8s (data not shown). Further, we found that MT1-MMP, which has a functional relationship with MMP-2 (Seiki, 2003) , was overexpressed at least 2-3-fold in the pRc-9 cell line at both the levels of mRNA (Figure 1a, b) and protein ( Figure 1c ). Since MT1-MMP protein levels correlate with mRNA expression levels, we focused our studies on VHL regulation of MT1-MMP gene expression.
VHL expression inhibits MT1-MMP transcription and HIF-2a protein levels
To study VHL regulation of MT1-MMP transcription, we measured MT1-MMP nascent heteronuclear (hn) RNA production in the RCC cell lines using quantitative real-time RT-PCR. The pRc-9 cells had elevated levels of MT1-MMP hnRNA compared to the WT8s (Figure 2a) , demonstrating that the overexpression of MT1-MMP in the pRc-9s (see Figure 1 ) is a result of increased transcription in these cells. Furthermore, treatment with Actinomycin D showed no significant difference in the mRNA decay curves between the cell lines (data not shown), supporting the conclusion that the difference in MT1-MMP expression is due to transcriptional effects rather than mRNA stability effects. Next, VHL regulation of MT1-MMP gene expression was confirmed by transient overexpression of a VHL expression construct in the pRc-9 cells. Transfection efficiency was high enough to measure the effects of VHL expression on endogenous gene expression. Overexpression of wild-type VHL in the pRc-9 cells showed a dose-dependent decrease in endogenous MT1-MMP gene expression and HIF-2a protein levels, suggesting a role for HIF-2a in MT1-MMP regulation (Figure 2b, c) . To define the region of the MT1-MMP promoter that was responsive to negative regulation by VHL, a VHL expression construct was co-transfected with a 0.4 kb fragment of the MT1-MMP promoter (0.4MT-luc) into HEK293 cells, used for their ease of transfection. Overexpression of VHL significantly repressed expression of the MT1-MMP promoter construct, indicating that at least some elements by which VHL regulates MT1-MMP gene expression are present in the proximal promoter (Figure 2d ). Similar results were obtained using the pRc-9 cells (data not shown).
MT1-MMP transcription is regulated by HIF-2a
When VHL function is lost, HIF-a protein is stabilized and forms a heterodimer with HIF-b, and target hypoxia-inducible genes are transcribed. The RCC cell lines used in these studies express only the HIF-2a isoform (Maxwell et al., 1999) , and we postulated that HIF-2a may mediate the increase in MT1-MMP transcription in the pRc-9 cells.
To test whether transient HIF-2a overexpression could activate a promoter containing HIF-binding sites in a wild-type VHL background, the WT8s were cotransfected with the pTK-RE3-luc reporter with either expression constructs, pCMV-HIF2a or pCMV-HIFb, or with the two expression constructs together.
Transient overexpression of pCMV-HIF2a alone was sufficient to induce the pTK-RE3-luc reporter construct in the WT8 cells (Figure 3a) . Additionally, co-expression of pCMV-HIF2a with pCMV-HIFb did not induce the promoter further than pCMV-HIF2a alone, suggesting that endogenous HIF-b levels are sufficient to dimerize with transiently expressed HIF-2a and transactivate the reporter construct. This result is in agreement with the findings of Tian et al. (1997) . As expected, the expression of pCMV-HIFb alone did not drive expression of the reporter since HIF binds DNA as a heterodimer (Jiang et al., 1996) .
Given these results, HIF-2a regulation of MT1-MMP in the WT8 cells was tested by transient overexpression of pCMV-HIF2a with the 0.4MT-luc promoter construct. Overexpression of HIF-2a induced the MT1-MMP promoter in the WT8 cells in a dose-responsive manner ( Figure 3b ). Thus, forced HIF-2a expression leads to the upregulation of MT1-MMP transcription in the presence of wild-type VHL, suggesting that HIF-2 mediates MT1-MMP overexpression in VHL RCC. In order to confirm HIF-2a regulation of endogenous MT1-MMP gene expression, a third RCC cell line (W þ 2PA) was used that stably expressed wild-type VHL and a variant of HIF-2a, which is not degraded by VHL (Figure 3c ) (Kondo et al., 2002a) . Similar to the pRc-9 cells, the W þ 2PA cells express elevated levels of MT1-MMP hnRNA compared to the WT8 cells (Figure 3d) , showing that cells which have stable HIF2a protein expression overexpress MT1-MMP.
Identification of a HIF-2 binding site at À125 in the MT1-MMP promoter
To determine whether HIF-2a regulates MT1-MMP transcription directly on the MT1-MMP promoter or indirectly through the activation of another transcription factor(s) which could then target MT1-MMP, we searched the proximal 0.4 kb promoter for HIF-binding sites (HBSs). Two putative HBSs (HBS1 À125 and HBS2 þ 144 ) were identified, and the sequences are conserved in the mouse MT1-MMP promoter, suggesting possible functionality (Figure 4 ). The WT8 cells were co-transfected with the pCMV-HIF2a expression construct and either the 0.4 kb MT1-MMP promoter construct, which contains the HBSs at À125 and þ 144, or a 0.1 kb MT1-MMP promoter construct, which has only the HBS site at þ 144. Interestingly, HIF-2a was unable to induce the 0.1 kb promoter fragment, lending support to the HBS at À125 as the functional HIF site (Figure 5a ).
To confirm this finding, multi-site-directed mutagenesis was used to mutate each HBS in the MT1-MMP promoter (Table 1) . Wild-type and mutated promoter constructs were transfected alone in the WT8 cells, which do not express HIF-2a protein (see Figure 3c ), and no difference in expression was measured (data not shown). However, when the mutated promoter constructs were transiently co-expressed with the pCMVHIF2a expression construct in the WT8 cells, HIF-2a induced expression was impaired by mutation of HBS1 Figure 5b ). Mutation of HBS1 (À125) reduced expression of the MT1-MMP promoter by approximately 40%, whereas mutation of HBS2 ( þ 144) had no effect. Likewise, mutation of both HBSs did not significantly reduce expression beyond that which was observed with HBS1 mutated alone (B50% reduction), again suggesting that HBS1 is the functional HIF-2 binding site.
Similar results were obtained when the mutated promoter constructs were expressed alone in the pRc-9 cells (Figure 5c ), which express high levels of endogenous HIF-2a (see Figure 3c) , demonstrating that endogenous levels of HIF-2a resulting from the loss of VHL can regulate expression of the HBS constructs. These data give further support to HBS1 as the site by which VHL regulates MT1-MMP via a HIF-2a dependent mechanism. Interestingly, a slight but statistically significant reduction (20%) in expression of the DHBS2 construct was observed in the pRc-9 cells, and mutation of both HBSs reduced expression in an additive manner (40% for HBS1, 20% for HBS2, 60% for both) (Figure 5c ). These data suggest that HBS2 is also regulated by HIF-2 in these cells and that this site may be functional in the pRc-9 cells. Since this effect was not observed in the WT8 cells, it is possible that overexpression of HIF-2a in the WT8s overwhelms the promoter such that minor effects on transcription, which are otherwise apparent when looking at the effects of the endogenous transcription factor (as in the pRc-9s), are missed.
Proximal Sp1 site is necessary for basal expression and full HIF-2a induction of MT1-MMP
As shown in Figure 5 , mutation of HBS1 did not fully abrogate expression of MT1-MMP, suggesting that other mechanisms or factors contribute to its regulation. MT1-MMP has a TATA-less promoter, and basal expression is driven by a proximal Sp1 site at À92 from the transcriptional start site (see Figure 4 and Lohi et al., 2000) . We confirmed that basal transcription of MT1-MMP is dependent on this Sp1 site in the WT8 cell line by measuring the expression of the 0.4MT-luc promoter construct and the 0.4MT-luc promoter construct with the Sp1 site mutated (0.4DSp1MT-luc) in the WT8 cells (Figure 6a ). Many genes have recently been identified in which HIF-1 and Sp1 have a coordinate relationship in their transcriptional regulation, such as RORa, Endoglin, and EPO1 (Sanchez-Elsner et al., 2002; Miki et al., 2004; Sanchez-Elsner et al., 2004) . Therefore, we hypothesized that HIF-2 induces MT1-MMP in coordination with Sp1. To test the possible cooperativity between the Sp1 and HBS1 sites, the 0.4MT-luc and 0.4DSp1MT-luc constructs were co-transfected with or without pCMV-HIF-2a in the WT8 cells. Interestingly, mutation of the Sp1 site abrogated HIF-2a induction of the MT1-MMP promoter by more than 50%, suggesting that these transcription factors function coordinately in the induction of MT1-MMP (Figure 6b) .
To confirm these results, we used WP631, a bisanthracycline that competitively binds to the G/C-rich sequence of Sp1 sites with an affinity similar to protein, to inhibit Sp1-mediated transcription at nanomolar concentrations (Martin et al., 1999; Gaidarova and Jimenez, 2002) . WT8 cells were co-transfected with 0.4 kb of the MT1-MMP promoter and the pCMVHIF2a expression construct and treated with WP631. HIF-2a induced expression of the MT1-MMP promoter was inhibited in a dose-responsive manner with WP631 treatment (Figure 6c ), again suggesting that these transcription factors are functioning coordinately at the MT1-MMP promoter. Taken together, these results show that Sp1 is necessary for full HIF-2 induction of MT1-MMP.
Discussion
Although VHL disease manifests itself as several different types of cancer, the most common cause of morbidity and mortality in these patients is metastatic renal cell carcinoma (Richards et al., 1998; Singh et al., 2001) . Less than 20% of patients with metastatic RCC will survive 5 years beyond diagnosis (Linehan et al., 2003) . Interestingly, over 90% of RCC patients with Stage I disease will survive this 5-year period (Linehan et al., 2003) ; therefore, determining the events leading to metastatic RCC will provide therapeutic approaches to prevent progression to later stages of disease. Here we describe that, in addition to MMP-2 and -9, the loss of VHL leads to the upregulation of MT1-MMP, a membrane-tethered MMP which orchestrates many key aspects of tumor cell invasion and metastasis (Sato et al., 1994; Hotary et al., 2000; Mori et al., 2002; Seiki, 2003) . Importantly, we demonstrate that the increase in MT1-MMP expression is the result of transcriptional activation by HIF-2, thereby providing a link between VHL tumor suppressor function and MT1-MMP expression.
We identified MT1-MMP as a new target of HIF-2. Thus, our data imply that MT1-MMP is a hypoxiainducible gene and that HIF-2 regulation of MT1-MMP may play a role in other cancers in which HIF is upregulated. Since HIF-1 and HIF-2 bind to the same recognition sequence (Tian et al., 1997) , it is probable that HIF-1 may induce MT1-MMP expression as well. Given the essential role of HIF in a tumor's response to hypoxia (Harris, 2002) and the contribution of MT1-MMP to the angiogenic process and tumor cell invasion (Egeblad and Werb, 2002; Seiki, 2003) , it is reasonable to hypothesize that the upregulation of MT1-MMP documented in human cancers occurs in response to the hypoxic environment within the growing tumor. In fact, hypoxia has been shown to increase MT1-MMP expression in other cell types by currently undefined mechanisms (Kondo et al., 2002b; Annabi et al., 2003; Ottino et al., 2004) . However, it is also possible that the upregulation of MT1-MMP by HIF-2 is specific to renal cell carcinoma, thereby providing an explanation as to why these VHL tumors are so invasive. Interestingly, VHL tumors differ in their expression of the HIF-a isoforms with some tumors types expressing exclusively one isoform and others both (Maxwell et al., 1999) . Moreover, studies show that these two isoforms have limited overlap in their target gene profiles and exhibit cell-type-specific expression with low redundancy (Tian et al., 1997; Jain et al., 1998; Wiesener et al., 1998; Giatromanolaki et al., 2001) . Interestingly, inhibition of HIF-2a is both necessary and sufficient for tumor suppression by VHL in renal cell carcinoma in vivo (Kondo et al., 2002a (Kondo et al., , 2003 Zimmer et al., 2004) , whereas inhibition of HIF-1a is not (Maranchie et al., 2002) . These findings suggest that HIF-2a behaves as a renal oncogene in the context of VHL disease. Normal epithelial cells do not express MT1-MMP (Seiki, 2003) ; therefore, given the role of MT1-MMP in cancer progression, we propose that HIF-2 induction of MT1-MMP expression may contribute to the oncogenic effects attributed to HIF-2a in RCC.
Our data show a cooperation of HIF-2 and Sp1 in the induction of MT1-MMP expression; however, other factors must contribute to HIF-2 activation of MT1-MMP gene expression given that mutations of both the functional HBS and Sp1 sites did not fully abrogate induced expression. One explanation for this result may be attributed to signaling through the chemokine receptor, CXCR4. CXCR4 is a hypoxia-inducible gene, and its upregulation due to the loss of VHL leads to increased invasiveness of RCC cells in response to its ligand, stromal-derived factor 1 (SDF-1) (Staller et al., 2003) . Although the mechanism of how CXCR4 signaling enhances RCC tumor cell invasion has not been defined, a recent study in melanoma cells showed Table 1 Site-directed mutagenesis of MT1-MMP promoter
Regulation of MT1-MMP by HIF-2a in VHL renal cell carcinoma BL Petrella et al expressing MT1-MMP was sufficient to suppress cell migration and invasion. Furthermore, Maquoi et al. (2004) showed in their recent studies that an orally active MMP inhibitor, selective for MT1-MMP, MMP-2, and MMP-9, prevented tumor cell invasion in vitro and had antitumor and antiangiogenic activities in vivo.
Our data define a direct link between the loss of the VHL tumor suppressor and the upregulation of MT1-MMP. Designing specific therapies, such as targeting MT1-MMP expression, may prove effective at preventing metastatic RCC disease and reduce the need for radical, invasive surgeries for VHL patients.
Materials and methods
Cell lines and cell culture
All cell lines were maintained in Dulbecco's modified Eagle's medium (Life Technologies, Inc.) supplemented with 10% fetal bovine serum (Cambrex), penicillin 100 U/ml, streptomycin 100ug/mL, and L-glutamine and cultured at 371C, 5% CO 2 . The WT8 and pRc-9 cell lines (kindly provided by William Kaelin, Dana-Farber Cancer Institute, Boston, MA, USA) were derived from the human 786-0 renal cell carcinoma cell line, which has a single VHL allele harboring a frameshift mutation at codon 104 resulting in a truncated, nonfunctional protein (Iliopoulos et al., 1995) . 786-0 subclones stably transfected with pRc/CMV-HA-VHL (WT8) or pRc/CMV empty (pRc-9) were selected with the addition of 1 mg/mL G418 sulfate. The WT8 cells were additionally stably transfected with pBabe-puro-HA-HIF2a, designated W þ 2PA (also provided by William Kaelin). pBabe-puro-HA-HIF2a contains two mutations (P405A, P531A), which abrogate prolyl-hydroxylation of HIF-2a, thereby inhibiting its interaction with VHL with no effect on the function of HIF2a (Kondo et al., 2002a) . The W þ 2PA cell line was selected with 1 mg/mL G418 sulfate and 1.5 mg/mL puromycin. HEK 293 cell line was purchased from American Type Culture Collection (ATCC). For endogenous gene expression experiments, cell lines were grown to confluence, washed three times in HBSS, and cultured in serum-free medium for 24 h. For transfection studies, cell lines were transfected in serumcontaining medium in the absence of antibiotics for 18 h. MT1-MMP expression was not regulated by the presence or absence of serum (data not shown).
Reagents and plasmids
WP631 was obtained from Calbiochem. pGL3-Basic-0.4MT-luc, pGL3-Basic-0.4DSp1MT-luc, and pGL3-Basic-0.1MT-luc constructs have been described previously (Lohi et al., 2000) . Briefly, these reporter constructs contain 0.4 or 0.1 kb of the 5 0 -flanking region of the MT1-MMP gene linked to the firefly luciferase gene. The 0.4MT-luc construct contains wild-type promoter sequence, whereas the 0.4DSp1MT-luc construct contains mutations in the functional Sp1 site at -92, which abrogate binding and transactivation by Sp1. The 0.1 kb construct does not contain a functional Sp1 site.
MT1-MMP HBS mutant constructs were generated using the QuikChange Multi Site-Directed Mutagenesis Kit (Stratagene) following the manufacturer's protocol. The 0.4MT-luc promoter construct was used in the mutagenesis to create reporter plasmids which contained one or both of the putative HBSs mutated (Table 1 ). The oligos used in the mutagenesis were designed from the MT1-MMP sequence (GenBank accession #AF158733) using Stratagene's web-based primer design software found at http://labtools.stratagene.com/QC. DHBS-1 (À125) was created by mutating the sequence 5 0 -CACGTC-3 0 to 5 0 -CTTTTC-3 0 . DHBS-2 ( þ 144) was created by mutating the sequence 5 0 -GGCGTG-3 0 to 5 0 -GGAAAG-3 0 . Underlined nucleotides represent the mutated bases of the HBS consensus sequence. Mutations were confirmed by DNA sequence analysis. pTK-RE3-luc reporter plasmid contains three copies of a 50 nt hypoxia-inducible enhancer from the erythropoietin gene and has been shown to be inducible by coexpression of HIF-2a (Tian et al., 1997) . The pTK-RE3-luc, pCMV-HIF-2a, and pCMV-HIFb expression constructs were generous gifts of Richard Bruick (University of Texas, Southwestern Medical Center, Dallas, TX, USA). pRc/ CMV-HA-VHL expression construct was a kind gift from William Kaelin. pRc/CMV empty vector was created from pRc/CMV-HA-VHL by HindIII/XbaI digest to remove the HA-VHL insert and was religated using HindIIIÀXm-XmnI þ XbaIÀXmnI adaptors (NE Biolabs).
Northern blotting
Total cellular RNA was purified from using TRIzol Reagent (Invitrogen). Total RNA (10 mg/lane) was separated by electrophoresis using 1% agarose formaldehyde gels and transferred to GeneScreen Plus membranes (NEN Lifesciences). Membranes were hybridized with a denatured MT1-MMP cDNA probe, labeled with a-32 P-dCTP by random oligo priming. Ethidium bromide-stained 28S rRNA was used as a loading control.
Real-time RT-PCR
Total cellular RNA was purified using either the TRIzol Reagent (Invitrogen) and subjected to DNase treatment (Ambion DNA-free kit) or the RNeasy kit (Qiagen) with oncolumn DNase treatment. RT was performed using the Applied Biosystems Taqman Reverse Transcription Reagent Kit, following the manufacturer's protocol. Briefly, 4 mg of DNase-treated RNA was used per 40 ml reaction (5.5 mM MgCl 2 , 500 mM of each dNTP, 2.5 mM oligod(T) 16 , 0.4 U/ml RNase Inhibitor, 1.25 U/ml Multiscribe enzyme). Alternatively, an MT1-MMP antisense primer, which is specific for exon 2, was used in the RT reactions in order to enrich for MT1-MMP RNAs. RT reactions were incubated at 25 1C for 5 min, 481C for 30 min, and 951C for 5 min. Real-time PCR reactions were performed using the Applied Biosystems Sybr Green master mix. In all, 500 ng of input cDNA was used in each real-time PCR reaction analyzing MT1-MMP expression, while 100 ng of input cDNA was used in each real-time PCR reaction analyzing GAPDH expression. Each cDNA was assayed in triplicate using an MJ Research DNA Engine Opticon thermal cycler using the following parameters: 951C 10 min, 40 cycles of 951C 15 s, 601C 1 min, and a plate read.
Standard curves were included in each assay. Standards for MT1-MMP mRNA and hnRNA were generated by serial log dilutions of the appropriate PCR product ranging from 10 to 0.01 pg, and 0.1 to 0.0001 pg, respectively. Standards for GAPDH expression were generated using serial log dilutions ranging from 1 to 0.001 ng of the pCMV sport6 plasmid (ATCC). Primer sequences are as follows: MT1-MMP mRNA: 
Immunoblotting
Whole-cell lysates were harvested from confluent six-well plates cultured in serum-free medium for 24 h by washing the cells twice with cold 1 Â PBS, adding 150 ml of lysis buffer (50 mM Tris-HCl, pH 6.8, 1% SDS, 1 mM EDTA, pH 8.0, protease inhibitor cocktail) or SDS reducing buffer (60 mM Tris-HCl, pH 6.8, 2% SDS, 14.4 mM b-mercaptoethanol, 25% glycerol, 0.1% bromphenol blue), and boiling for 5 min. Proteins were resolved by SDS-PAGE and electrotransferred to Immobilon-P PVDF membranes (Millipore). Membranes were blocked with 5% milk in Tris-buffered saline 0.1% Tween-20 at room temperature for 1-2 h. Primary antibodies were diluted in blocking buffer and incubated with the membranes overnight at 41C with rocking. Appropriate secondary antibodies were diluted in blocking buffer and incubated with the membrane at room temperature for 1 h. Proteins were visualized by the Western Lightning Chemiluminescence Reagent (Perkin-Elmer). Antibodies and dilutions were as follows: VHL monoclonal antibody, 1 : 100 (Neomarkers, Clone Ig33); HA-HRP monoclonal antibody, 1 : 500 (Sigma); HIF-2a polyclonal antibody, 1 : 1000 (Novus Biologicals, NB100-122); actin monoclonal antibody, 1 : 5000 (Oncogene, Ab-1); anti-mouse HRP-conjugated antibody, 1 : 5000 (Santa Cruz Biotechnology); and anti-rabbit HRPconjugated antibody, 1 : 2000 (Santa Cruz Biotechnology).
MT1-MMP ELISA
The Matrix Metalloproteinase-14 (MMP-14) Biotrak Activity Assay System (Amersham Biosciences), a quantitative measure of MT1-MMP activity, was used to analyse MT1-MMP protein expression. Cells were plated in serum-containing media in triplicate and harvested at confluence with the extraction buffer provided in the kit. The assay was conducted according to the manufacturer's protocol. A standard curve ranging from 0.125 to 32 ng/ml was used to quantitate protein expression. As the assay is colorimetric and does not require quenching, the plate was read at 2.5, 6, and 9 h after incubation with the substrate. The data represent the 6 h timepoint since the values obtained at this time fit the standard curve most appropriately. Values are presented as average protein concentration normalized to average cell number at time of harvest (n ¼ 3).
Transient transfections
Cell lines were plated at a density of 2 Â 10 5 cells/well in sixwell plates. When cells were 95% confluent, they were transiently transfected with 2-4 mg of DNA using Lipofectamine 2000t Transfection Reagent (Invitrogen) following manufacturer's instructions. In co-transfection and expression construct dose-response studies, empty vector controls were used to balance the concentration of transfected DNA. All transfections were performed in triplicate. Approximately 18 h later, cells were washed in cold 1 Â PBS and lysed using 25 mM glycylglycine, 4 mM EGTA, 15 mM MgSO 4 , 1% Triton X-100 for luciferase assays or total RNA was harvested using the RNeasy kit as described under real-time RT-PCR. Luciferase assays were run using a LMaxII 384 Luminometer (Molecular Devices). Transfection efficiency was determined as the percentage of GFP-expressing cells counted from three fields of three separate transfections. Values are presented either as relative luciferase units (RLUs) of representative data or as mean control values from three or more experiments.
Statistical analysis
Statistical significance was calculated using the student's t-test available at http://www.physics.csbsju.edu/stats/t-test.html and are represented as 7 standard deviation (s.d.) of the mean. Significance was assigned to P-values o0.05.
